Otonomy, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2008-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.otonomy.com
Clinical Trials
33
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (33 trials with phase data)• Click on a phase to view related trials
OTO-313 in Subjects With Unilateral Subjective Tinnitus
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Otonomy, Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT04829214
- Locations
- 🇺🇸
Central California Clinical Research, Fresno, California, United States
🇺🇸Breathe Clear Institute, Torrance, California, United States
🇺🇸University of Colorado, Department of Otolaryngology, Aurora, Colorado, United States
OTO-413 in Subjects With Speech-in-Noise Hearing Impairment
- First Posted Date
- 2019-10-17
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Otonomy, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT04129775
- Locations
- 🇺🇸
Colorado Otolaryngology Associates LLC dba Colorado ENT & Allergy, Colorado Springs, Colorado, United States
🇺🇸Research Centers of America, Hollywood, Florida, United States
🇺🇸South Florida ENT Associates or Research Centers of America, Miami, Florida, United States
OTO-313 in Subjects With Subjective Tinnitus
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Otonomy, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT03918109
- Locations
- 🇺🇸
House Clinic, Los Angeles, California, United States
🇺🇸California Head & Neck Specialists, San Diego, California, United States
🇺🇸Colorado ENT and Allergy, Colorado Springs, Colorado, United States
Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Otonomy, Inc.
- Target Recruit Count
- 148
- Registration Number
- NCT03664674
- Locations
- 🇺🇸
Central California Clinical Research, Fresno, California, United States
🇺🇸University of Colorado School of Medicine, Aurora, Colorado, United States
🇺🇸Colorado ENT & Allergy, Colorado Springs, Colorado, United States
Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Otonomy, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02997189
- Locations
- 🇺🇸
Contact Otonomy call center for trial locations, San Diego, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next